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Abstract
Background: Rhegmatogenous retinal detachment (RRD) is a major cause of visual loss in developed countries. Proliferative
vitreoretinopathy (PVR), an eye-sight threatening complication of RRD surgery, resembles a wound-healing process with
inflammation, scar tissue formation, and membrane contraction. This study was performed to determine the possible
involvement of a wide range of cytokines in the future development of PVR, and to identify predictors of PVR and visual
outcome.
Methodology: A multiplex immunoassay was used for the simultaneous detection of 29 different cytokines in subretinal
fluid samples from patients with primary RRD. Of 306 samples that were collected and stored in our BioBank between 2001
and 2008, 21 samples from patients who developed postoperative PVR were compared with 54 age-, sex-, and storage-
time–matched RRD control patients who had an uncomplicated postoperative course during the overall follow-up period.
Findings: Levels of IL-1a, IL-2, IL-3, IL-6, VEGF, and ICAM-1 were significantly higher (P,0.05) in patients who developed
postoperative PVR after reattachment surgery than in patients with an uncomplicated postoperative course, whereas levels
of IL-1b, IL-4, IL-5, IL-7, IL-9, IL-10, IL-11, IL-12p70, IL-13, IL-15, IL-17, IL-18, IL-21, IL-22, IL-23, IL-25, IL-33, TNF-a, IFN-c, IGF-1,
bFGF, HGF, and NGF were not (P.0.05). Multivariate logistic regression analysis revealed that IL-3 (P=0.001), IL-6 (P=0.047),
ICAM-1 (P=0.010), and preoperative visual acuity (P=0.026) were independent predictors of postoperative PVR. Linear
regression analysis showed that ICAM-1 (P=0.005) and preoperative logMAR visual acuity (P=0.001) were predictive of final
visual outcome after primary RRD repair.
Conclusions/Significance: Our findings indicate that after RRD onset an exaggerated response of certain cytokines may
predispose to PVR. Sampling at a time close to the onset of primary RRD may thus provide clues as to which biological
events may initiate the development of PVR and, most importantly, may provide a means for therapeutic control.
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Introduction
Rhegmatogenous retinal detachment (RRD) is an ophthalmo-
logic emergency that occurs in approximately 12.6 cases per
100,000 persons per year [1]. Although an increasingly number of
retinal detachments is successfully repaired with a single
procedure, proliferative vitreoretinopathy (PVR) is still the
primary cause of failure of reattachment surgery [1]. This eye-
sight threatening condition is characterized by the formation of
cellular membranes on both sides of the retina that upon
contraction may cause a redetachment with often a permanent
drop in visual acuity. The development of these fibrotic
membranes is reminiscent of the normal wound-healing response
with inflammation, migration and proliferation of resident ocular
cells and invading immune cells [2]. In all these biological
processes, cytokines function as signalling molecules between these
cells in order to bring about the events that ultimately lead to the
formation and contraction of PVR membranes [2].
Several studies have been undertaken to unravel the role of
these cytokines in the pathogenesis of PVR by determining their
expression in PVR vitreous and PVR membranes [2–12].
Resident ocular cells including retinal pigment epithelial (RPE)
cells and glial cells, and invading immune cells such as
macrophages and lymphocytes are all capable of producing and
secreting these cytokines [2]. Immunohistochemical studies have
demonstrated the presence of fibroblast growth factor (FGF),
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(VEGF) in PVR membranes [3,4]. For example, FGF and IGF
have been implicated in the migration and proliferation of RPE
cells [5,6], whereas VEGF may play a role in monocyte
chemotaxis [7]. Moreover, levels of interleukin (IL)-1, IL-6,
interferon (IFN)-c, and intercellular adhesion molecule (ICAM)-1
have been shown to be elevated in PVR vitreous [8–12],
suggesting an inflammatory component in PVR pathogenesis.
These data also indicate that not a single cytokine but a complex
network of cytokines may underlie the development of contractile
fibrotic membranes that are characteristic of PVR.
So far, the use of intravitreal pharmacological agents to prevent
the occurrence of PVR has shown disappointing results [13,14].
Although the intraoperative application of daunorubicin demon-
strated some effect by reducing the number of reoperations, its use
failed to show a significant increase in reattachment rate in
patients with preoperative PVR [15]. A better understanding of
the early biological alterations after primary RRD that may lead to
postoperative PVR is therefore needed to develop new therapeutic
strategies. Previous animal studies have demonstrated an increase
in gene and protein expression of proinflammatory cytokines hours
and days after the creation of experimental retinal detachment
when no PVR membranes have formed yet [16,17]. However,
previous studies have mainly focused on cytokines in ocular fluids
of patients with established PVR [11,12,18–21]. Further, only a
limited number of cytokines have been determined in each patient
in these studies. Since PVR is the resultant of an inflammatory
process in which a multitude of cytokines is involved, the
measurement of a single cytokine seems rather unsatisfactory.
Therefore, examining a whole cytokine profile in patients after
primary RRD provides not only clues as to which cytokines may
play a role in PVR pathogenesis, it may also indicate which
cytokines are most predictive of its development.
In a previous study on early biological alterations after primary
RRD, we used recently developed multiplex bead-based immu-
noassays for the simultaneous detection of several chemokines and
their correlation with IL-6 [22]. In the study presented here we
report the protein expression of 29 different interleukins and
growth factors in subretinal fluid samples from the same
population. Our findings indicate that an exaggerated response
of certain cytokines occurring after RRD onset may predispose to
PVR development.
Materials and Methods
Patients
The research followed the tenets of the Declaration of Helsinki
and the Medical Ethics Committee of University Hospital
Maastricht, which approved all the protocols used in this study.
All enrolled patients gave written informed consent before the
surgical procedure and after the nature of the study was explained.
Subretinal fluid samples are routinely collected during scleral
buckling surgery for primary RRD in our department, except in
patients with small (less than one quadrant) or shallow detach-
ments. Between 2001 and 2008, a total of 306 patients underwent
subretinal fluid sampling. Upon collection, samples were trans-
ferred and stored in the BioBank Maastricht. A thorough medical
record study revealed that 45 of these patients developed a
redetachment due to PVR later on during the postoperative
follow-up period. Of these, 9 samples were excluded due to low
sample volume (,75 mL) or contamination with blood, whereas 6
samples were excluded because of late PVR development (more
than 2K months after subretinal fluid collection). Further, we
excluded 4 patients with preoperative vitreous hemorrhage, 4
patients with preoperative trauma, and 1 patient with preoperative
cryotherapy. Finally, 21 samples from patients who developed a
redetachment due to PVR within 2K months after scleral
buckling surgery for primary RRD were included in the study.
This disease group, defined as the PVR group, was compared with
patients who did not develop a redetachment during the overall
follow-up period (at least 3 months), i.e. patients with an
uncomplicated follow-up after primary RRD repair. Samples
from these patients served as controls and were defined as the
RRD group. We compared every single PVR sample with two to
three age-, sex-, and storage-time–matched controls, which
resulted in 54 control patients with an uncomplicated follow-up
following primary retinal detachment surgery.
Sample Collection
Undiluted subretinal fluid samples were obtained during scleral
buckling surgery for primary RRD. Scleral and choroidal vessels
were carefully cauterized before the incision. Any macroscopic
blood surrounding the incision opening was removed with a cotton
tip. Subretinal fluid was collected from the surface of the sclera
with a 25-gauge bent needle. All samples were collected in sterile
polypropylene tubes, stored at 280uC, and thawed directly before
analysis. Sample volumes ranged between 100–700 mL.
Multiplex Bead-Based Immunoassay
Cytokines were measured at the Luminex Core Facility
(Utrecht, The Netherlands) with a multiplex immunoassay
(Luminex, Austin, TX, USA) using an in-house-validated panel
which incorporates an appropriate Quality Control Program, as
previously described [23]. In summary, the antibody-coated
microspheres were incubated for 60 minutes with standards or
subretinal fluid (50 mL) in 96-well, 1.2-mm filter plates (Millipore,
Amsterdam, The Netherlands). Plates were washed (Bio-Plex pro
II wash station, Bio-Rad, Hercules, CA, USA), and a cocktail of
biotinylated detection antibodies was added for an additional
60 minutes. After repeated washings streptavidin–phycoerythrin
was added and incubated for 10 minutes. Next, after 2 additional
washes fluorescence intensity was measured. Data collection and
analysis of the data from all assays were performed (Bio-Plex
system in combination with Bio-Plex Manager software, ver. 4.1;
Bio-Rad, Hercules, CA, USA), by using five-parameter curve
fitting. The concentrations of the following cytokines were
measured: the interleukins IL-1a, IL-1b, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-7, IL-9, IL-10, IL-11, IL-12p70, IL-13, IL-15, IL-17, IL-
18, IL-21, IL-22, IL-23, IL-25, and IL-33; the proinflammatory
cytokines tumor necrosis factor (TNF)-a and IFN-c; the growth
factors IGF-1, basic (b)FGF, VEGF, nerve growth factor (NGF),
and hepatocyte growth factor (HGF); and the cell adhesion
molecule ICAM-1. The lower limit of detection of the cytokines
ranged between 0.1 and 19.5 pg/mL. Concentrations below the
detection limit were assigned the lowest value from the respective
standard curve. For statistical analysis, concentrations below the
detection limit were converted to a value of 0.5 times the lowest
value of the calibration curve.
Clinical Variables
For all patients, demographic variables, potential clinical risk
factors for the development of PVR (Table 1) and the following
clinical variables were collected: follow-up time, occurrence of a
redetachment, postoperative PVR grade, and preoperative and
final postoperative best corrected Snellen visual acuity. PVR was
graded according to the Classification of Retinal Detachment with
PVR [24]. Data were collected as 0 (no PVR), 1 (grade A), 2 (grade
B), 3 (grade C), and 4 (grade D). Duration of retinal detachment
Cytokines in Rhegmatogenous Retinal Detachment
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surgery and was estimated according to a precise history of
patients’ symptoms. Duration of macular detachment was
evaluated separately and was defined as the interval between the
onset of a sudden drop in visual acuity and reattachment surgery.
The refraction of pseudophakic patients was evaluated based on
historical data. For statistical analysis, Snellen visual acuity was
transformed into logMAR visual acuity.
Statistical Analysis
Patients who developed a redetachment due to PVR within 2K
months after the scleral buckling procedure (the PVR group) were
compared with patients with an uncomplicated follow-up (the
RRD group). Further, we investigated whether cytokine concen-
trations were different in patients who developed early postoper-
ative PVR (within 30 days after reattachment surgery) compared
to patients with late postoperative PVR (more than 30 days after
reattachment surgery) and whether differences in cytokine
expression were related to PVR grade. The nonparametric
Mann-Whitney U test was used for ordinal variables such as
analyte levels, since data were not normally distributed. The chi-
square test was used to compare nominal variables such as
diabetes mellitus. Correlations were determined by the Spear-
man’s rho test. As we expected that preoperative PVR, duration of
retinal detachment, and macular involvement were not equally
distributed between both groups, we investigated the role of these
clinical parameters as possible confounding variables with respect
to the association between cytokine levels and the development of
postoperative PVR, using multivariate logistic regression analysis.
Statistical analysis of the data was performed using SPSS version
16.0 (SPSS for Windows; SPSS, Chicago, IL, USA). Differences
were considered significant at P,0.05, with two-tailed testing.
Stepwise logistic regression analysis was used to assess the data’s
predictive ability in determining the occurrence of a redetachment
due to postoperative PVR. Since the choice of P,0.05 is often too
stringent in this analysis and may exclude important variables
from the model, choosing a higher P value is highly recommended
[25]. Therefore, clinical and biological variables that reached P
values,0.15 in univariate tests were further analyzed with forward
stepwise logistic regression analysis. Linear regression analysis was
used to assess the data’s predictive value in determining
postoperative visual acuity.
Results
Demographics and Clinical Results
Subretinal fluid samples from 75 patients who underwent scleral
buckling surgery were analyzed. Twenty one patients with primary
RRD who developed postoperative PVR within 2K months after
the surgical procedure were compared with 54 patients with
primary RRD who had an uncomplicated follow-up. The PVR
group consisted of 6 women (29%) and 15 men (71%) with a
median age of 62 years (range 43–76). The median time interval
between the scleral buckling procedure and redetachment due to
PVR was 37 days (range 13–80) and the median follow-up time
was 21 months (range 3–80). Ten patients developed a redetach-
ment due to postoperative PVR grade B, 10 patients due to
postoperative PVR grade C, and one patient due to postoperative
PVR grade D. In comparison, the RRD group included 14
women (26%) and 40 men (74%) with a median age of 61 years
(range 43–79). Their median follow-up time was 6 months (range
3–80).
Potential preoperative clinical risk factors for the development
of postoperative PVR were available for all 75 patients included in
this study (Table 1). There were no statistically significant
differences between both groups regarding these parameters,
except for a worse median preoperative logMAR visual acuity in
the PVR group (1.77; range 0.10–2.52) as compared to the RRD
group (0.75; range 0.05–2.52) (P=0.045). Although not statisti-
cally significant, median preoperative PVR grades were higher in
Table 1. Demographics and Potential Clinical Risk Factors for PVR.
Potential Clinical Risk Factor RRD Group (n=54) PVR Group (n=21) Univariate Testing
Stepwise Logistic
Regression
Age (years) 61 (43–79) 62 (43–76) NS NS
Sex, Female (%) 26 29 NS NS
Size of retinal detachment (quadrants) 2 (1–3) 2 (1–4) NS NS
Total size of retinal defects (optic disc diameters) 2 (0–5.5) 1 (0–4) NS NS
Macular detachment (%) 64 86 NS NS
Preoperative logMAR VA 0.75 (0.05–2.52) 1.77 (0.10–2.52) P=0.045 P=0.026
Detachment duration (days) 5 (1–75) 6 (1–90) NS NS
Preoperative PVR grade 1 (0–3) 2 (0–3) NS NS
Diabetes mellitus (%) 11 10 NS NS
Preoperative myopia .5 D ( % )1 72 4N S N S
Pseudophakia (%) 19 33 NS NS
Aphakia (%) 0 0 NS NS
Preoperative uveitis (%) 0 0 NS NS
Preoperative cryotherapy (%) 0 0 NS NS
Preoperative vitreous hemorrhage (%) 0 0 NS NS
Preoperative trauma (%) 0 0 NS NS
Data are expressed as median (range) or in percentages. Abbreviations: RRD=rhegmatogenous retinal detachment; PVR=proliferative vitreoretinopathy; NS=not
significant; logMAR=logarithm of minimal angle of resolution; VA=visual acuity; D=diopters.
doi:10.1371/journal.pone.0019141.t001
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(P=0.218), as well as the median duration of retinal detachment
(PVR, 6 days; RRD, 5 days) (P=0.650) and the percentage of
patients with macular involvement (PVR, 86%; RRD 64%)
(P=0.067).
Interleukin and Growth Factor Levels in Subretinal Fluid
Among the interleukins analyzed, levels of IL-1a (P=0.025), IL-
2( P=0.044), IL-3 (P=0.008), IL-6 (P,0.001), IL-15 (P=0.013),
and IL-18 (P=0.008) were significantly higher in patients with
primary RRD who developed a redetachment due to PVR than in
patients with primary RRD and an uncomplicated follow-up.
Since small nonsignificant differences in baseline characteristics
between both groups may have influenced our results, we decided
to correct for preoperative PVR grade, duration of retinal
detachment, and macular involvement using multivariate logistic
regression analysis. After correction, levels of IL-1a (P=0.011), IL-
2( P=0.021), IL-3 (P=0.006), and IL-6 (P=0.021) remained
significantly elevated in the PVR group as compared to the RRD
group, whereas both IL-15 (P=0.392) and IL-18 (P=0.281) lost
their significance.
Levels of IGF-1, bFGF, NGF, and HGF were similar between
both groups (P.0.05), whereas median VEGF levels were
approximately two to three times higher in the PVR group as
compared to the RRD group (P=0.012). After correction for the
aforementioned preoperative clinical parameters, this difference
remained statistically significant (P=0.049). In the current study,
we found wide variations in the levels of both IL-6 and VEGF with
approximately a 100-fold increase of the highest levels compared
to the lowest levels in both the PVR and RRD group.
IFN-c was detected in 9 of 54 (17%) subretinal fluid samples
from patients in the RRD group and in 3 of 21 (14%) samples
from patients in the PVR group (P.0.05). There were no
significant differences in the median levels of IFN-c and TNF-a
between the two groups (P.0.05). The median levels of the cell
adhesion molecule ICAM-1 were significantly elevated in the PVR
group as compared to the RRD group (P=0.002), even after
having corrected for differences in preoperative PVR grade,
duration of retinal detachment, and macular involvement
(P=0.016). Levels of all cytokines are summarized in Table 2;
levels of cytokines that were significantly different between both
groups are illustrated in Fig. 1.
To find out whether there were differences in cytokine levels
between patients with different postoperative PVR grades within
the PVR group, we compared patients with postoperative PVR
grade B (n=10) to patients with postoperative PVR grade C or
higher (n=11). Median IL-6 levels were significantly higher in the
PVR grade B group (245 pg/mL, range 116–2656) as compared
to the PVR grade C group (114 pg/mL, range 36–1398)
(P=0.024). No other significant differences in cytokine levels were
detected between both groups. Comparison of cytokines between
patients who developed postoperative PVR within 30 days (n=8)
and those who developed PVR after 30 days following surgery
(n=13) did not reveal any significant differences.
Correlations of Biological Variables and Clinical Variables
There were moderate to strong correlations between IL-1a and
both IL-2 and IL-3 (r=0.83 and r=0.64, respectively) (P,0.001)
and between IL-2 and IL-3 (r=0.47) (P,0.001). Further, we found
a strong correlation between VEGF and ICAM-1 (r=0.61). When
comparing cytokine levels with clinical variables, we generally
found low correlations (r,0.4) except between duration of macular
detachment and ICAM-1 (r=0.40) (P,0.01). With respect to
preoperative PVR grade, we only found a very weak association
with ICAM-1 levels (r=0.25) (P=0.030). Preoperative visual
acuity correlated moderately but significantly with final visual
acuity (r=0.43) (P,0.001). Correlations between other preoper-
ative clinical variables (i.e. duration of retinal detachment,
duration of macular detachment, the extent of retinal detachment
in quadrants, and the number of retinal breaks) and final visual
acuity were very low (r,0.3), whereas patients with macular
detachment at the time of primary retinal detachment surgery had
worse final visual outcome (median logMAR VA 0.52, range 0–
3.00) as compared to patients without involvement of the macula
(median logMAR VA 0.30, range 0–0.80) (P=0.013).
Predictors of Postoperative PVR and Visual Outcome
Variables that were significantly different between the RRD
group and the PVR group or were close to significance in
univariate tests (P,0.15) were selected for stepwise logistic
regression analysis. The selected variables were IL-1a, IL-2, IL-
3, IL-6, IL-15, IL-18, IL-25, NGF, VEGF, ICAM-1, preoperative
logMAR visual acuity and presence of macular detachment. This
analysis revealed that IL-3 (P=0.001), IL-6 (P=0.047), ICAM-1
(P=0.010), and preoperative logMAR visual acuity (P=0.026)
were independent predictors of postoperative PVR after primary
RRD. On the other hand, linear regression analysis showed that
ICAM-1 (P=0.005) and preoperative logMAR visual acuity
(P=0.001) were predictive of final visual outcome after primary
RRD repair.
Discussion
In the current study, we found levels of IL-1a, IL-2, IL-3, IL-6,
VEGF, and ICAM-1 to be significantly higher in patients who
developed a redetachment due to postoperative PVR than in
patients with an uncomplicated follow-up after primary RRD.
Correction for possible confounding variables including preoper-
ative PVR, duration of retinal detachment, and macular
involvement was necessary due to small differences in baseline
characteristics between the PVR group and the RRD group.
Stepwise forward logistic regression analysis revealed that IL-3, IL-
6, ICAM-1, and preoperative visual acuity were independent
predictors of postoperative PVR, whereas ICAM-1 and preoper-
ative visual acuity were predictive of final visual acuity after
primary RRD repair. Samples from patients with preoperative
conditions known to induce PVR were excluded from the study,
since these would have yielded high cytokine levels that were
directly related to that condition (e.g., uveitis). In addition, we
excluded samples from patients with late PVR development,
considering it would be more likely that in patients who have PVR
developed after 3 months, a new event caused the recurrence
rather than the stimulus that was of our interest [26]. Hence, our
findings indicate that there is an association between certain
cytokines (IL-1a, IL-2, IL-3, IL-6, VEGF, and ICAM-1) and the
development of postsurgical PVR after primary RRD repair.
Whether an unknown clinical event may have triggered the
exaggerated cytokine response in the PVR group or whether
differences in the genetic control of this cytokine response are
involved remains to be clarified.
Animal studies have shown an upregulation of proinflammatory
genes already very soon (hours to days) after the induction of
retinal detachment together with a time dependency of certain
cytokines [16,17]. These animal studies are certainly far more
well-controlled than our clinical study and a time dependency
could not be analyzed due to insufficient time points. Nevertheless,
we demonstrated that sampling after the onset of primary RRD
but before the development of postoperative PVR may provide
Cytokines in Rhegmatogenous Retinal Detachment
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membranes, and may therefore provide a means for therapeutic
control before postoperative PVR has been established. In the
scope of developing a preventive strategy, a study by Bali et al [27]
showed that a single preoperative subconjunctival injection of
dexamethasone prior to scleral buckling retinal detachment
surgery resulted in a significant decrease in laser flare measure-
ments at one week postoperatively, reflecting less blood-retina
barrier breakdown. Whether steroid priming via these injections
leads to a lower incidence of postoperative PVR has not yet been
investigated.
Multiplex bead-based immunoassay allowed us to detect a large
number of cytokines simultaneously, with comparable perfor-
mance in sensitivity, accuracy, and reproducibility to enzyme-
linked immunosorbent assays (ELISAs) performed in previous
studies [28]. With the use of ELISAs, earlier studies could only
focus on a few cytokines and mostly studied patients with already
established PVR following earlier reattachment surgery. More-
over, most studies have dealt with vitreous samples, whereas our
study addressed subretinal fluid specimens. To discover early
biological alterations that may lead to PVR development, analysis
of subretinal fluid may be more appropriate because of its close
proximity to the RPE cell layer after initial retinal detachment.
The source of the cytokines in our subretinal fluid specimens
remains speculative although it is most likely that they are
simultaneously produced by resident ocular cells and infiltrating
inflammatory cells. Even though the blood-retina barrier may be
broken down, the levels of plasma cytokines do not reach high
enough levels to significantly contribute to the cytokine milieu in
the subretinal space after retinal detachment [18,19,29].
A large number of ocular fluid cytokines has been investigated
previously in RRD patients with or without PVR, including IL-1,
IL-6, TNF-a, IFN-c, VEGF, FGF, HGF, and ICAM-1 (Table S1)
[8–12,18–21,29–33]. Of this group of cytokines, we confirmed
earlier findings showing elevated levels of IL-1a, IL-6, VEGF, and
ICAM-1 in our specimens. Comparison of the levels reported in
these studies is however difficult due to significant differences in
sampling time, sampling size, sampling specimen, laboratory
Table 2. Cytokine Levels and the Development of Postoperative PVR.
Cytokine (pg/mL) RRD Group (n=54) PVR Group (n=21) Univariate testing
Stepwise Logistic
Regression
IL-1a 5.8 (2.9–11) 7.0 (4.1–20) P=0.025 NS
IL-1b 6.4 (2.5–12) 6.8 (3.1–20) NS NS
IL-2 5.9 (3.7–12) 6.6 (3.4–18) P=0.044 NS
IL-3 101 (24–348) 144 (47–464) P=0.008 P=0.001
IL-4 1.5 (0.5–2.8) 1.7 (1.0–4.5) NS NS
IL-5 2.3 (0.8–4.5) 2.2 (0.9–6.3) NS NS
IL-6 60 (8.3–1211) 149 (36–2656) P,0.001 P=0.047
IL-7 16 (6.2–63) 17 (6.7–53) NS NS
IL-9 103 (49–185) 96 (54–288) NS NS
IL-10 3.5 (1.7–8.4) 3.8 (2.3–8.5) NS NS
IL-11 23 (7.3–59) 25 (12–89) NS NS
IL-12p70 32 (15–58) 30 (19–78) NS NS
IL-13 59 (27–191) 57 (37–162) NS NS
IL-15 0.8 (0.1–15) 1.8 (0.3–11) P=0.013 NS
IL-17 37 (11–76) 32 (14–119) NS NS
IL-18 24 (5.8–262) 36 (12–144) P=0.008 NS
IL-21 3524 (2291–5481) 3421 (1981–7135) NS NS
IL-22 30 (6.6–81) 35 (9.4–98) NS NS
IL-23 133 (63–857) 135 (80–435) NS NS
IL-25 2349 (1253–65737) 2458 (1516–26189) NS NS
IL-33 14 (4.8–64) 17 (5.4–55) NS NS
TNF-a 6.2 (2.9–8.8) 6.6 (2.1–30) NS NS
IFN-c ,0.3 (,0.3–16) ,0.3 (,0.3–18) NS NS
IGF-1 1548 (1086–2344) 1607 (1106–3401) NS NS
bFGF 1137 (715–2051) 1154 (767–2869) NS NS
NGF 7.0 (2.8–9.6) 7.5 (2.8–31) NS NS
HGF 3413 (413–9987) 3949 (971–10769) NS NS
VEGF 64 (21–1421) 153 (40–3308) P=0.012 NS
ICAM-1 19927 (4529–40489) 28276 (6780–44606) P=0.002 P=0.010
Data are expressed as median (range) in pg/mL. Abbreviations: RRD=rhegmatogenous retinal detachment; PVR=proliferative vitreoretinopathy; IL=interleukin;
NS=not significant; TNF-a=tumor necrosis factor-a; IFN-c=interferon-c; IGF-1=insulin growth factor-1; bFGF=basic fibroblast growth factor; NGF=nerve growth
factor; HGF=hepatocyte growth factor; VEGF=vascular endothelial growth factor; ICAM-1=intercellular adhesion molecule-1.
doi:10.1371/journal.pone.0019141.t002
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correlation between increased levels of IL-2 and IL-3 and the
development of postoperative PVR as we describe in the current
study has not yet been reported earlier.
The proinflammatory cytokines IL-1a and IL-1b have similar
biological properties and have been implicated in the pathogenesis
of PVR [8,9]. Since IL-1 induces RPE cell migration [34] and its
intravitreal injection leads to breakdown of the blood-ocular
barrier [35], IL-1 has been suggested to be an important candidate
in the activation processes that ultimately lead to PVR
development. Although our findings showed that IL-1a levels
were significantly elevated in the PVR group, the difference with
the control group was only small. The same holds for IL-2 with
median levels of less than 7 pg/mL. On the other hand, many
cytokines have redundant properties and even small elevations in a
number of cytokines may lead to synergistic effects.
IL-6 reached very high levels in some patients and median levels
were approximately 2.5 times higher in the PVR group as
compared to the RRD group. IL-6 is a pleiotropic cytokine with a
wide range of activities in inflammation and immune reactions
[36]. Various groups have reported IL-6 gene expression and
secretion by cytokine-stimulated human RPE cells [37,38],
whereas IL-6 may also be produced by several inflammatory cells
invading the subretinal space after RRD due to chemotactic
signalling [39]. In addition, IL-6 itself was found to induce
chemokines and to amplify the recruitment of leukocytes in an
animal model [40]. Consistent with these data, we reported the
correlation between IL-6 and a wide range of chemokines in
subretinal fluid samples from patients with retinal detachment
[22]. IL-6, in contrast, may also serve as a photoreceptor
neuroprotectant, as was shown in an experimental model of
retinal detachment [41]. Results of our current study were in line
with those of Kon et al [8] and El-Ghrably et al [9], suggesting a
role for IL-6 in the early alterations that may induce postoperative
PVR (Table S1). Interestingly, we found significantly lower IL-6
levels in patients with higher postoperative PVR grades, for which
we have no sound explanation.
Similar to IL-6, we found median VEGF levels to be two to
three times elevated in subretinal fluid samples of patients with
PVR. Since PVR is characterized by the formation of mainly
avascular membranes, it was hypothesized that VEGF may have
functions other than inducing angiogenesis [4]. This hypothesis
was supported by growing evidence of a possible interaction of
VEGF with non-endothelial cells in the eye. A previous study has
shown that RPE cells in situ, as well as RPE cells in epiretinal
membranes and in culture, express VEGF receptors [4]. In the
majority of these membranes, VEGF and its receptors were co-
localized, indicating that an autocrine and/or paracrine mecha-
nism may exist. Other studies identified VEGF receptors on other
non-endothelial cells in the eye such as on adult photoreceptor
cells and Mu ¨ller cells, implicating a role for VEGF in the
maintenance of the adult neural retina by supporting cell survival
of these retinal cells [42]. Interestingly, VEGF has also been shown
to induce monocyte activation manifested by the induction of
Figure 1. Box-and-whisker plots of significantly elevated cytokine levels in patients with primary rhegmatogenous retinal
detachment. A multiplex immunoassay was used to determine 29 different cytokines in subretinal fluid samples obtained during scleral buckling
surgery for rhegmatogenous retinal detachment. Patients who developed a redetachment due to postsurgical PVR within 2K months after
reattachment surgery (n=21, ‘PVR’ group) were compared with controls who had an uncomplicated retinal detachment during the overall follow-up
period (n=54, ‘RRD’ group). Levels of IL-1a, IL-2, IL-3, IL-6, VEGF, and ICAM-1 were significantly higher (P,0.05) in patients who developed
postoperative PVR than in patients with an uncomplicated postoperative course. After correction for possible confounding variables including
preoperative PVR, duration of retinal detachment, and macular involvement, these factors remained significantly different between both groups (see
text). Box: lower and upper quartiles; horizontal line: the median. Abbreviations: PVR=proliferative vitreoretinopathy; RRD=rhegmatogenous retinal
detachment; IL=interleukin; VEGF=vascular endothelial growth factor; ICAM-1=intercellular adhesion molecule-1.
doi:10.1371/journal.pone.0019141.g001
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pic effects on diverse cell types such as RPE cells and monocytes,
which play major roles in the development of PVR.
The presence of ICAM-1 in epiretinal membranes and vitreous
of patients with PVR has been demonstrated earlier in a few
studies [43,44]. In addition, ICAM-1 expression has been found
on cultured human RPE cells and was upregulated after
stimulation with IL-1, TNF-a, or IFN-c [45]. ICAM-1 has an
important role in regulating leukocyte migration into sites of
inflammation, thereby enhancing cytokine-mediated inflammatory
reactions after retinal detachment. Limb and Chignell [10]
showed that high levels of ICAM-1 may constitute an additional
risk factor to known clinical risk factors for the development of
PVR. Our study confirmed these results, and we showed that
ICAM-1 is not only an independent predictor of postoperative
PVR, but also of visual outcome after reattachment surgery.
The use of multiplex immunoassays entails research that is
basically hypothesis-generating. We identified IL-2 and IL-3 as
novel candidates in the activation of PVR development. Elevated
concentrations of these cytokines in our samples suggest their
involvement in the initial stages of PVR pathogenesis. IL-3, which
was shown to be the best predictor of postoperative PVR in our
study population, exerts proinflammatory actions by the activation
of hematopoietic cells of various lineages including macrophages
[46], and is mainly synthesized by T-lymphocytes [47]. Together
with studies showing their presence in ocular fluids and epiretinal
membranes from patients with PVR [48,49], our results
underscore a possible role for T lymphocytes in the pathogenesis
of PVR. Since microglial cells have also been shown to express IL-
3 [50], its cellular source and function after retinal detachment
remain unknown.
So far, the use of intravitreal pharmacologic agents has not been
proven to be efficacious in the prevention or treatment of PVR
and most efforts have been dedicated to modulate the clinical risk
factors [13,14]. Despite these efforts PVR is still the primary cause
of failure of retinal detachment surgery and a frequent cause of
legal blindness in developed countries. Therefore, more insight in
its pathogenesis is needed to develop further prevention strategies.
The identification of laboratory predictors of PVR (IL-3, IL-6,
ICAM-1) may help us to treat only those patients at greatest risk.
On the other hand, the identification of preoperative visual acuity
as an independent predictor of postoperative PVR should be
viewed with caution since it is merely a result of statistical analysis
and is most likely due to a higher proportion of patients with
macular involvement in the PVR group. Future prospective
studies are necessary to test the validity of our study. Since we only
assessed cytokine content in subretinal fluid samples from patients
who underwent scleral buckling surgery for primary RRD,
predictors of postoperative PVR derived from our study results
may not be applicable to other patient populations (e.g., patients
who undergo a vitrectomy). The present study did not include
known PVR associated factors such as platelet-derived growth
factor (PDGF) or transforming growth factor (TGF)-b [30,51].
The PDGF assay has not yet been developed by the Luminex Core
Facility, whereas the TGF-b assay needs a prior acid activation to
convert the latent into the activated form, which prevents its
simultaneous detection with other cytokines in the multiplex bead
immunoassay.
In summary, our findings show that several cytokines are
upregulated after the onset of RRD in patients in whom
postoperative PVR develops after primary RRD repair. An
exaggerated inflammatory response in this subset of patients may
thus be the underlying phenomenon that ultimately leads to the
formation of PVR membranes. Moreover, we report that IL-3, IL-
6, ICAM-1, and preoperative visual acuity were independent
predictors of PVR and may be useful in identifying those patients
at greatest risk. Importantly, elevated levels of IL-3 may shed new
light on PVR pathogenesis and may suggest T cell and/or
microglial cell involvement in the early events of PVR develop-
ment.
Supporting Information
Table S1 Summary of cytokine levels in RRD patients with and
without PVR.
(DOC)
Author Contributions
Conceived and designed the experiments: LJAGR AK ECLH. Performed
the experiments: WdJ. Analyzed the data: LJAGR AK FH ECLH.
Contributed reagents/materials/analysis tools: WdJ ATAL FH ECLH.
Wrote the paper: LJAGR AK ECLH.
References
1. D’Amico DJ (2008) Clinical practice. Primary retinal detachment. N Engl J Med
359: 2346–2354.
2. Pastor JC, de la Ru ´a ER, Martı ´n F (2002) Proliferative vitreoretinopathy: risk
factors and pathobiology. Prog Retin Eye Res 21: 127–144.
3. Fredj-Reygrobellet D, Baudouin C, Ne `gre F, Caruelle JP, Gastaud P, et al.
(1991) Acidic FGF and other growth factors in preretinal membranes from
patients with diabetic retinopathy and proliferative vitreoretinopathy. Ophthal-
mic Res 23: 154–161.
4. Chen YS, Hackett SF, Schoenfeld CL, Vinores MA, Vinores SA, et al. (1997)
Localisation of vascular endothelial growth factor and its receptors to cells of
vascular and avascular epiretinal membranes. Br J Ophthalmol 81: 919–926.
5. Spraul CW, Kaven C, Lang GK, Lang GE (2004) Effect of growth factors on
bovine retinal pigment epithelial cell migration and proliferation. Ophthalmic
Res 36: 166–171.
6. Grant MB, Guay C, Marsh R (1990) Insulin-like growth factor I stimulates
proliferation, migration, and plasminogen activator release by human retinal
pigment epithelial cells. Curr Eye Res 9: 323–335.
7. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, et al. (1990) Vascular
permeability factor: a tumor-derived polypeptide that induces endothelial cell
and monocyte procoagulant activity, and promotes monocyte migration. J Exp
Med 172: 1535–1545.
8. Kon CH, Occleston NL, Aylward GW, Khaw PT (1999) Expression of vitreous
cytokines in proliferative vitreoretinopathy: a prospective study. Invest
Ophthalmol Vis Sci 40: 705–712.
9. El-Ghrably IA, Dua HS, Orr GM, Fischer D, Tighe PJ (2001) Intravitreal
invading cells contribute to vitreal cytokine milieu in proliferative vitreoretino-
pathy. Br J Ophthalmol 85: 461–470.
10. Limb GA, Chignell AH (1999) Vitreous levels of intercellular adhesion molecule
1 (ICAM-1) as a risk indicator of proliferative vitreoretinopathy. Br J Ophthalmol
83: 953–956.
11. Kauffmann DJH, Van Meurs JC, Mertens DAE, Peperkamp E, Master C, et al.
(1994) Cytokines in vitreous humor: interleukin-6 is elevated in proliferative
vitreoretinopathy. Invest Ophthalmol Vis Sci 35: 900–906.
12. La Heij EC, Van de Waarenburg MP, Blaauwgeers HG, Kessels AGH,
Liem ATA, et al. (2002) Basic fibroblast growth factor, glutamine synthetase,
and interleukin-6 in vitreous fluid from eyes with retinal detachment
complicated by proliferative vitreoretinopathy. Am J Ophthalmol 134: 367–
375.
13. Wickham L, Bunce C, Wong D, McGurn D, Charteris DG (2007) Randomized
controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in
the management of unselected rhegmatogenous retinal detachments undergoing
primary vitrectomy. Ophthalmology 114: 698–704.
14. Ahmadieh H, Feghhi M, Tabatabaei H, Shoeibi N, Ramezani A, et al. (2008)
Triamcinolone acetonide in silicone-filled eyes as adjunctive treatment for
proliferative vitreoretinopathy: a randomized clinical trial. Ophthalmology 115:
1938–1943.
15. Wiedemann P, Hilgers RD, Bauer P, Heimann K (1998) Adjunctive
daunorubicin in the treatment of proliferative vitreoretinopathy: results of a
multicenter clinical trial. Daunomycin Study Group. Am J Ophthalmol 126:
550–559.
16. Hollborn M, Francke M, Iandiev I, Bu ¨hner E, Foja C, et al. (2008) Early
activation of inflammation- and immune response-related genes after experi-
mental detachment of the porcine retina. Invest Ophthalmol Vis Sci 49:
1262–1273.
Cytokines in Rhegmatogenous Retinal Detachment
PLoS ONE | www.plosone.org 7 April 2011 | Volume 6 | Issue 4 | e1914117. Nakazawa T, Matsubara A, Noda K, Hisatomi T, She H, et al. (2006)
Characterization of cytokine responses to retinal detachment in rats. Mol Vis 12:
867–878.
18. Canataroglu H, Varinli I, Ozcan AA, Canataroglu A, Doran F, et al. (2005)
Interleukin (IL)-6, interleukin (IL)-8 levels and cellular composition of the
vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretino-
pathy, and traumatic proliferative vitreoretinopathy. Ocul Immunol Inflamm
13: 375–381.
19. Su CY, Chen MT, Wu WS, Wu WC (2000) Concentration of vascular
endothelial growth factor in the subretinal fluid of retinal detachment. J Ocul
Pharmacol Ther 16: 463–469.
20. Mitamura Y, Takeuchi S, Matsuda A, Tagawa Y, Mizue Y, et al. (2000)
Hepatocyte growth factor levels in the vitreous of patients with proliferative
vitreoretinopathy. Am J Ophthalmol 129: 678–680.
21. Ogata N, Nishikawa M, Nishimura T, Mitsuma Y, Matsumura M (2002) Inverse
levels of pigment epithelium-derived factor and vascular endothelial growth
factor in the vitreous of eyes with rhegmatogenous retinal detachment and
proliferative vitreoretinopathy. Am J Ophthalmol 133: 851–852.
22. Ricker LJAG, Kijlstra A, De Jager W, Liem ATA, Hendrikse H, et al. (2010)
Chemokine levels in subretinal fluid obtained during scleral buckling surgery
after rhegmatogenous retinal detachment. Invest Ophthalmol Vis Sci 51:
4143–4150.
23. de Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V (2009)
Prerequisites for cytokine measurements in clinical trials with multiplex
immunoassays. BMC Immunol 10: 52.
24. Retina Society Terminology Committee (1983) The classification of retinal
detachment with proliferative vitreoretinopathy. Ophthalmology 90: 121–125.
25. Hosmer DW, Lemeshow S (1989) Model-building strategies and methods for
logistic regression. In: Shewhart WA, Wilks SS, eds. Applied logistic regression.
New York: Wiley. pp 82–134.
26. Mietz H, Heimann K (1995) Onset and recurrence of proliferative vitreoretino-
pathy in various vitreoretinal diseases. Br J Ophthalmol 79: 874–877.
27. Bali E, Feron EJ, Peperkamp E, Veckeneer M, Mulder PG, et al. (2010) The
effect of a preoperative subconjunctival injection of dexamethasone on blood-
retinal barrier breakdown following scleral buckling retinal detachment surgery:
a prospective randomized placebo-controlled double blind clinical trial. Graefes
Arch Clin Exp Ophthalmol 248: 957–962.
28. de Jager W, Te Velthuis H, Prakken BJ, Kuis W, Rijkers GT (2003)
Simultaneous detection of 15 human cytokines in a single sample of stimulated
peripheral blood mononuclear cells. Clin Diagn Lab Immunol 10: 133–139.
29. Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y, Enaida H, et al. (2009)
Comprehensive analysis of inflammatory immune mediators in vitreoretinal
diseases. PLoS ONE 4: e8158.
30. Dieudonne ´ SC, La Heij EC, Diederen R, Kessels AGH, Liem ATA, et al. (2004)
High TGF-b2 levels during primary retinal detachment may protect against
proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 45: 4113–4118.
31. Banerjee S, Savant V, Scott RAH, Curnow SJ, Wallace GR, et al. (2007)
Multiplex bead analysis of vitreous humor of patients with vitreoretinal
disorders. Invest Ophthalmol Vis Sci 48: 2203–2207.
32. Rasier R, Gormus U, Artunay O, Yuzbasioglu E, Oncel M, et al. (2010)
Vitreous levels of VEGF, IL-8, and TNF-alpha in retinal detachment. Curr Eye
Res 35: 505–509.
33. Dieudonne ´ SC, La Heij EC, Diederen RMH, Kessels AGH, Liem ATA, et al.
(2007) Balance of vascular endothelial growth factor and pigment epithelial
growth factor prior to development of proliferative vitreoretinopathy. Ophthal-
mic Res 39: 148–154.
34. Kirchhof B, Kirchhof E, Ryan SJ, Dixon JF, Barton BE, et al. (1989)
Macrophage modulation of retinal pigment epithelial cell migration and
proliferation. Graefes Arch Clin Exp Ophthalmol 227: 60–66.
35. Ferrick MR, Thurau SR, Oppenheim MH, Herbort CP, Ni M, et al. (1991)
Ocular inflammation stimulated by intravitreal interleukin-8 and interleukin-1.
Invest Ophthalmol Vis Sci 32: 1534–1539.
36. Kishimoto T (2006) Interleukin-6: discovery of a pleiotropic cytokine. Arthritis
Res Ther 8(Suppl 2): S2.
37. Kuppner MC, McKillop-Smith S, Forrester JV (1995) TGF-beta and IL-1 beta
act in synergy to enhance IL-6 and IL-8 mRNA levels and IL-6 production by
human retinal pigment epithelial cells. Immunology 84: 265–271.
38. Holtkamp GM, Van Rossem M, de Vos AF, Willekens B, Peek R, et al. (1998)
Polarized secretion of IL-6 and IL-8 by human retinal pigment epithelial cells.
Clin Exp Immunol 112: 34–43.
39. de Vos AF, Hoekzema R, Kijlstra A (1992) Cytokines and uveitis, a review. Curr
Eye Res 11: 581–597.
40. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, et al. (1997) Role
of IL-6 and its soluble receptor in induction of chemokines and leukocyte
recruitment. Immunity 6: 315–325.
41. Chong DY, Boehlke CS, Zheng QD, Zhang L, Han Y, et al. (2008) Interleukin-6
as a photoreceptor neuroprotectant in an experimental model of retinal
detachment. Invest Ophthalmol Vis Sci 49: 3193–3200.
42. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, et al. (2008)
Endogenous VEGF is required for visual function: evidence for a survival role on
Mu ¨ller cells and photoreceptors. PLoS ONE 3: e3554.
43. Limb GA, Franks WA, Munasinghe KR, Chignell AH, Dumonde DC (1993)
Proliferative vitreoretinopathy: an examination of the involvement of lympho-
cytes, adhesion molecules and HLA-DR antigens. Graefes Arch Clin Exp
Ophthalmol 231: 331–336.
44. Esser P, Bresgen M, Fischbach R, Heimann K, Wiedemann P (1995)
Intercellular adhesion molecule-1 levels in plasma and vitreous from patients
with vitreoretinal disorders. Ger J Ophthalmol 4: 269–274.
45. Elner SG, Elner VM, Pavilack MA, Todd RF, 3rd, Mayo-Bond L, et al. (1992)
Modulation and function of intercellular adhesion molecule-1 (CD54) on human
retinal pigment epithelial cells. Lab Invest 66: 200–211.
46. Frendl G, Beller DI (1990) Regulation of macrophage activation by IL-3. I. IL-3
functions as a macrophage-activating factor with unique properties, inducing Ia
and lymphocyte function-associated antigen-1 but not cytotoxicity. J Immunol
144: 3392–3399.
47. Lindemann A, Mertelsmann R (1993) Interleukin-3: structure and function.
Cancer Invest 11: 609–623.
48. Charteris DG, Hiscott P, Robey HL, Gregor ZJ, Lightman SL, et al. (1993)
Inflammatory cells in proliferative vitreoretinopathy subretinal membranes.
Ophthalmology 100: 43–46.
49. Baudouin C, Hofman P, Brignole F, Bayle J, Loubie `re R, et al. (1991)
Immunocytology of cellular components in vitreous and subretinal fluid from
patients with proliferative vitreoretinopathy. Ophthalmologica 203: 38–46.
50. Gebicke-Haerter PJ, Appel K, Taylor GD, Schobert A, Rich IN, et al. (1994)
Rat microglial interleukin-3. J Neuroimmunol 50: 203–214.
51. Lei H, Rheaume MA, Kazlauskas A (2010) Recent developments in our
understanding of how platelet-derived growth factor (PDGF) and its receptors
contribute to proliferative vitreoretinopathy. Exp Eye Res 90: 376–381.
Cytokines in Rhegmatogenous Retinal Detachment
PLoS ONE | www.plosone.org 8 April 2011 | Volume 6 | Issue 4 | e19141